Status:
COMPLETED
Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
Lead Sponsor:
University of Manitoba
Collaborating Sponsors:
The Kidney Foundation of Canada
Conditions:
Hemodialysis Complication
Infectious Disease
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to optimize the dosing of cefazolin, ceftazidime, and ciprofloxacin for patients on high-flux hemodialysis. For each antibiotic 20 participants will be enrolled and three blood samples...
Detailed Description
The goal of this study is to optimize the dosing of three commonly used antibiotics, thereby improving the treatment of serious, often life-threatening infections in patients on intermittent high-flux...
Eligibility Criteria
Inclusion
- \>18 years old
- Proven or suspected infection
- Receiving cefazolin, ceftazidime, or ciprofloxacin for treatment
- Treatment course allows for collection of three 6 mL blood samples as per protocol
Exclusion
- Chronic liver disease, Child Pugh Class C or higher
- Received study drug as part of a different treatment course in 1-week preceding start of new treatment course
- Acute kidney injury or recovering kidney function
Key Trial Info
Start Date :
October 18 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04319328
Start Date
October 18 2019
End Date
April 30 2024
Last Update
May 16 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Boniface Hospital, Outpatient Hemodialysis Unit
Winnipeg, Manitoba, Canada, R2H 2A6
2
College of Pharmacy, University of Manitoba
Winnipeg, Manitoba, Canada, R3E 0T5